Palisade Bio appoints Dr. Herbert Slade as Chief Medical Officer effective Nov 17, 2022

PALISADE BIO, INC.

Dr. Slade will serve as part-time consultant CMO with annual compensation of $240,000.
He had been consulting for the company since May 2022 and previously served as clinical advisor for LB1148.
Over 25 years of pharmaceutical/medical device leadership; previously CMO at Smith & Nephew, DFB Pharma, 3M Pharma.
No severance or termination benefits are provided in the consulting arrangement.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Herbert B. Slade

chief medical officer

PALI · PALISADE BIO, INC.

Effective: 2022-11-17
Filed: November 23, 2022, 6:59 PM ET

On November 17, 2022, the Board of Directors of Palisade Bio, Inc. (“Company”) appointed Herbert B. Slade, MD FAAAAI, to serve as the Company’s chief medical officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Herbert B. Slade was appointed as chief medical officer at PALISADE BIO, INC..

Action: appointed
Role: chief medical officer

Exact text from the filing

On November 17, 2022, the Board of Directors of Palisade Bio, Inc. (“Company”) appointed Herbert B. Slade, MD FAAAAI, to serve as the Company’s chief medical officer.

View on SEC.gov

PALISADE BIO, INC. filing history →

Source: SEC EDGAR

accession 0001493152-22-033543

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.